New mechanisms involved in the pathogenesis of osteosarcoma by Urciuoli, Enrica
Dottorato di Ricerca in Morfogenesi e Ingegneria Tissutale 
 Pag. 1  
 
 
 
SAPIENZA 
Università di Roma  
Facoltà di Farmacia e Medicina 
 
 
Dottorato di Ricerca in 
MORFOGENESI e INGEGNERIA TISSUTALE  
 
XXIX Ciclo  
(A.A. 2015/2016) 
 
 
 
 
New mechanisms involved in the pathogenesis of osteosarcoma 
 
 
 
Dottorando 
Enrica Urciuoli 
 
 
 
 
 
 
 
Tutor Coordinator 
Dr.ssa Barbara Peruzzi Prof. Sergio Adamo 
 
 
Enrica Urciuoli 
Pag 2  
Index 
 
1. The Thesis explained ............................................................... 4 
2. Introduction ............................................................................. 6 
2.1 Bone Tissue ....................................................................... 7 
The osteoblast and bone formation ......................................... 7 
The osteoclast and bone resorption ....................................... 10 
Bone remodeling ................................................................... 11 
2.2 Bone sarcoma: Osteosarcoma ......................................... 14 
Clinical aspects of osteosarcoma ........................................... 14 
Molecular pathogenesis of osteosarcoma .............................. 16 
Role of bone microenvironment in osteosarcoma 
development. ......................................................................... 18 
2.3 Extracellular Vesicles (EVs) ........................................... 18 
Isolation and characterization of EVs ................................... 20 
The molecular composition of EVs ....................................... 20 
Interaction of EVs with recipient cells .................................. 21 
3. Aims ...................................................................................... 24 
4. Results ................................................................................... 25 
4.1 Human osteosarcoma cancer cells produce extracellular 
vesicles. ..................................................................................... 25 
4.2 Osteosarcoma cell lines with different aggressiveness 
produce similar quantities of EVs. ............................................ 29 
4.3 Effects mediated by osteosarcoma-derived EVs on normal 
NIH3T3 cells. ............................................................................ 30 
CFSE
+
/PKH-26
+
 EVs fuse into NIH3T3 target cells. ........... 30 
The treatment with osteosarcoma derived-EVs improves 
NIH3T3 proliferation and survival in low-serum conditions.33 
Dottorato di Ricerca in Morfogenesi e Ingegneria Tissutale 
 Pag. 3  
NIH3T3 treated with osteosarcoma-derived EVs exhibited 
enhanced migration capability and an acquired anchorage-
independent growth. .............................................................. 38 
Osteosarcoma-derived EVs transfer osteogenic and tumour 
markers into recipient NIH3T3 cells. .................................... 40 
4.4 Effects of osteosarcoma-derived EVs on normal human 
bone cells. .................................................................................. 41 
Effects of osteosarcoma-derived EVs in Mesenchymal 
Stromal Cells (MSCs). .......................................................... 41 
Effects of osteosarcoma-derived EVs on human osteoblasts 
(hOBs). .................................................................................. 43 
Effects of osteosarcoma-derived EVs on human monocytes. 46 
4.5 To use EVs as prognostic/diagnostic markers. ............... 50 
4.6 To inhibit EV production in osteosarcoma cells. ............ 51 
5. Discussion ............................................................................. 52 
6. Materials & Methods ............................................................ 60 
6.1 Cell culture ...................................................................... 60 
6.2 EV collection .................................................................. 61 
6.3 Stainings and confocal microscopy analysis .................. 62 
6.4 Flowcytometric analysis ................................................. 62 
6.5 EV quantities analysis ..................................................... 63 
6.6 Western Blotting ............................................................. 63 
6.7 Apoptosis analysis .......................................................... 64 
6.8 Cell cycle analysis .......................................................... 64 
6.9 Wound healing assay ...................................................... 64 
6.10 Soft agar assay ................................................................ 64 
6.11 RT–PCR. ......................................................................... 65 
7. References ..................... Errore. Il segnalibro non è definito. 
Enrica Urciuoli 
Pag 4  
1. The Thesis explained 
 
Osteosarcoma is the most common and most often fatal primary 
bone tumour, especially affecting children and adolescents. It is a 
highly aggressive tumour that develops mainly in to the long bones 
and metastasizes primarily to the lung. Osteosarcoma cells are 
known to establish a crosstalk with resident bone cells leading to a 
deleterious vicious cycle.  
In this context, we hypothesized that osteosarcoma cells can 
release in the bone microenvironment transforming extracellular 
vesicles (EVs) involved in regulating the bone cell proliferation 
and differentiation, thereby promoting the tumour growth (Figure 
1). EVs are small, intact and heterogeneous membrane vesicles that 
exchange nucleic acids and proteins between cells, inducing 
phenotypic, biochemical and genetic changes in target cells.  
 
 
Figure 1. The work hypothesis of this study. 
We used human osteosarcoma cell lines to set protocols aimed at 
isolating, visualizing and characterizing EVs. Our results showed 
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that osteosarcoma cell lines produce EVs that are able to induce 
tumour phenotype in recipient murine fibroblasts NIH3T3, as 
already described for other cancer cell-derived EVs. Indeed, in EV-
treated NIH3T3, we observed an enhanced survival capability 
under low-serum conditions, high levels of activated survival 
pathways, an increased migration,  the acquired capability to grow 
in an anchorage-independent manner and a de novo expression of 
osteoblastic and tumourigenic markers. As regarding cells of the 
bone microenvironment, we used human osteoblasts and their 
precursors (mesenchymal stromal cells), as well as human 
osteoclasts and their precursors (monocytes), to assess the effects 
mediated by osteosarcoma-derived EVs. The EV treatment induced 
an increase of MSC differentiation into mature ALP
+ 
and Alizarin 
red
+
 osteoblasts. EVs derived from osteosarcoma cells promote the 
migration and the anchorage-independent growth of normal 
osteoblasts suggesting a transformation toward a tumour-like 
phenotype. Finally, monocytes treated with osteosarcoma EVs 
showed  an increased proliferation and the formation of TRAP
+
 
multinucleated osteoclasts, because of presence in EVs of 
cytokines involved in osteoclast activation and differentiation. 
These findings highlight the key role of EVs in the crosstalk 
between the osteosarcoma and bone microenvironment cells, 
suggesting that further investigation are needed to better define this 
new field of research. 
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2. Introduction 
 
 
 
 
 
 The human skeletal system consists of bones, cartilage, ligaments 
and tendons and accounts for about 20% of the body weight. The 
living bones in our bodies use oxygen and give off waste products 
in metabolism. They contain active tissues that consume nutrients, 
require a blood supply and change shape or remodel in response to 
variations in physiology and mechanical stress. Bones provide a 
rigid framework that supports the body against gravity and protect 
the soft organs. The adult human skeleton comprises 213 bones, 
each of which is sculpted by a process called modelling, and is 
constantly renewed by a process termed remodelling. Depending 
on its location, each bone supports one or more specific functions:  
 
 mechanical, support and site the muscle attachment 
for locomotion; 
 protective, for vital organs and bone marrow; 
 metabolic, as a reserve of ions, especially calcium 
and phosphate, for the maintenance of serum 
homeostasis, which is essential for life. 
1
 
 
As in all connective tissues, the fundamental constituents of bone 
are the cells and the extracellular matrix. The latter is particular 
abundant and is composed of collagen fibres and non-collagenous 
proteins. In bone and in the tissue forming the teeth, unlike those in 
other connective tissues, the matrices have the unique ability to 
became mineralized (or else have lost the ability to prevent 
mineralization)
2
.  
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2.1  Bone Tissue 
 
The osteoblast and bone formation 
Most of the bone-tissue turnover occurs at the bone surfaces, 
mainly at the endosteum interfacing with the bone marrow. This 
surface is morphologically heterogeneous, reflecting the various 
specific cellular activities involved in remodelling and turnover. 
The principal cells that mediate the bone forming processes of the 
mammalian skeleton are: osteoprogenitor cells, that contribute to 
maintaining the osteoblast population; osteoblasts, that synthesize 
the bone matrix on bone forming surfaces; osteocytes, organized 
throughout the mineralized bone matrix that support bone 
structure; and the protective bone surface lining cells. The fidelity 
of bone tissue structure and metabolic functions necessitates 
exchange of regulatory signals among these cell populations. 
Bone formation involves osteoblast maturation that requires a 
spectrum of signalling proteins including morphogens, hormones, 
growth factors, cytokines, matrix proteins, transcription factors, 
and their co-regulatory proteins. They act co-ordinately to support 
the temporal expression of other genes that represent the 
phenotypic, structural, and functional properties of osteoblasts 
during the differentiation process from osteoblast precursors. 
Osteoprogenitor cells will arise under the appropriate stimulus 
from stem cells present in many tissues in the adult organism. The 
bone marrow stroma contains cells with robust proliferative 
potential that will form single colonies (CFU-Fs) with the capacity 
to form bone, cartilage, adipocytes and fibroblasts when 
transplanted in vivo in diffusion chambers
3
. 
These CFU-Fs are now most commonly referred to as 
mesenchymal stromal cells (MSCs) and are distinguished from the 
hematopoietic stem cell (HSC) lineage. These precursors, with the 
right stimulation, undergo proliferation and differentiate into pre-
osteoblasts and then into mature osteoblasts.  
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Committed pre-osteoblasts are recognizable near the bone surface 
by their proximity to surface osteoblasts and by histochemical 
detection of alkaline phosphatase enzyme activity, one of the 
earliest markers of the osteoblast phenotype.  
The active mature osteoblast on the bone surface is distinguished 
by its morphological and ultrastructural properties, which are 
typical of a cell engaged in secretion of a connective tissue matrix, 
having a large and active nucleus, enlarged Golgi, and extensive 
rough endoplasmic reticulum.  
The osteoblast is highly enriched in alkaline phosphatase and 
vectorially secretes type I collagen and specialized bone matrix 
proteins as unmineralized osteoid toward the bone forming front. 
On quiescent bone surfaces, single layers of flattened osteoblasts 
or bone lining cells are observed. Osteoblasts and lining cells are in 
close contact with each other, joined by adherens junctions. Bone 
matrix synthesis by the osteoblast supports both cell–cell and cell–
matrix interactions that are mediated by transmembrane proteins  
and several classes of adhesion proteins. Integrins, which couple 
the extracellular matrix to the structural proteins of the 
cytoskeleton, mediate signals to modulate cell differentiation, 
cytoskeletal organization, cell adhesion, cell shape change, and cell 
spreading. The temporal expression of proteins involved in 
Figure 2. Growth and differentiation of osteoblasts. Schematic illustration of 
(A) osteoblast lineage cells and (B) frequently used markers of the stages of 
maturation.  
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extracellular matrix biosynthesis and matrix mineralization 
provides a panel of osteoblast phenotypic markers that reflects 
stages of osteoblast differentiation (Figure 2). Based on bone 
nodule formation in vitro, the process has been subdivided into 
three stages:  
 proliferation 
 extracellular matrix synthesis and maturation 
 mineralization, with characteristic changes in gene 
expression at each stage; apoptosis can also be seen in 
mature nodules. 
Expression of the osteoblast-associated genes type I collagen, 
alkaline phosphatase, osteopontin, osteocalcin, bone sialoprotein, 
and PTH/PTH-related protein receptor (PTH1R) is asynchronously 
upregulated and/or downregulated as the progenitor cells 
differentiate and matrix matures and mineralizes. In general, 
alkaline phosphatase and PTH1R are early markers of 
osteoprogenitors that increase as osteoblasts mature and deposit 
matrix but decline again with osteoblast transition to osteocytes, 
whereas osteocalcin is a late marker that is upregulated only in 
post-mitotic osteoblasts associated with mineralizing osteoid 
(Figure 2). When the pre-osteoblast ceases to proliferate, a key 
signalling event occurs for development of the large cuboidal 
differentiated osteoblasts on the bone surface from the spindle 
shaped osteoprogenitors. The osteoblast is responsible for 
synthesis of the extracellular matrix (ECM) leading to a “matrix 
maturation” stage when induced expression of alkaline 
phosphatase and specialized bone proteins render the ECM 
competent for mineral deposition. The composition and 
organization of the bone ECM is critical for structural and 
functional fidelity of bone tissue for constituents of the ECM. 
Mineralization results in upregulated expression of several non-
collagenous proteins, thereby providing markers of the mature 
osteoblasts. These calcium and phosphate binding proteins may 
function in regulating the ordered deposition of mineral, amount of 
the hydroxyapatite crystals, or crystal size. 
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The osteoclast and bone resorption 
The osteoclast, the exclusive bone resorptive cell, is a member of 
the monocyte/macrophage family and a polykaryon that can be 
generated in vitro from mononuclear phagocyte precursors resident 
in a number of tissues
4
. Two cytokines are essential and sufficient 
for basal osteoclastogenesis, Receptor Activator of Nuclear factor 
κB ligand (RANKL)3,5,6 and macrophage colony-stimulating factor 
(M-CSF). These two proteins, which exist as both membrane-
bound and soluble forms, are produced by marrow stromal cells 
and osteoblasts. RANKL, a member of the TNF superfamily, is the 
key osteoclastogenic cytokine, because osteoclast formation 
requires its presence or its priming of precursor cells. M-CSF 
contributes to the proliferation, survival, and differentiation of 
osteoclast precursors, as well as the survival and cytoskeletal 
rearrangement required for efficient bone resorption.. The unique 
osteoclastogenic properties of RANKL permit generation of pure 
populations of osteoclasts in culture and hence the performance of 
meaningful biochemical and molecular experiments that provide 
insights into the molecular mechanisms by which osteoclasts 
resorb bone. Key to the resorptive event is the capacity of the 
osteoclast to form a microenvironment between itself and the 
underlying bone matrix. This compartment, which is isolated from 
the general extracellular space, is acidified by an electrogenic 
proton pump (H
+
-ATPase) and a Cl
-
/H
+
 antiporter to a pH of ~4.5
7
. 
The acidified milieu mobilizes the mineralized component of bone, 
exposing its organic matrix, consisting largely of type 1 collagen 
that is subsequently degraded by the lysosomal enzyme, cathepsin 
K. Bone resorption also requires a polarization event in which the 
osteoclast delivers effector molecules like H
+
, Cl
-
 and cathepsin K 
into the resorptive microenvironment.  
Osteoclasts are characterized by a unique cytoskeleton, which 
mediates the resorptive process. Specifically, when the cell 
contacts the bone, it generates two polarized structures which 
enable it to degrade the skeletal tissue. In the first instance, a 
subset of acidified vesicles containing specific cargo, including 
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cathepsin K and other matrix metallo-proteases, are transported, 
probably through microtubules, to the bone-apposed plasma 
membrane
8
, to which they fuse in a manner not currently 
understood. Insertion of these vesicles into the plasmalemma 
results in the formation of a villous structure, unique to the 
osteoclast, the ruffled membrane. This resorptive organelle 
contains the abundant H
+
-transporting machinery to create the 
acidified microenvironment, while the accompanying exocytosis 
serves as the means by which lysosomal enzymes, including 
cathepsin K, are secreted. In addition to inducing ruffled 
membrane formation, contact with bone also prompts the 
osteoclast to polarize its fibrillar actin into a circular structure 
known as the actin ring. A separate sealing zone surrounds and 
isolates the acidified resorptive microenvironment underneath the 
active cell, termed resorbing lacuna. The actin ring, like the ruffled 
membrane, is a hallmark of the degradative capacity of the 
osteoclast.  
 
 
Bone remodelling  
Remodelling is accomplished by the collaborative and sequential 
efforts of a group of cells that are collectively termed the bone 
remodelling unit 
5
.  
There are four distinct phases in the remodelling cycle (Figure 3):  
 activation 
 resorption  
 reversal 
 formation  
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Activation describes the initiating event that transforms a 
previously quiescent bone surface into a remodelling one. 
Activation involves recruitment of mononucleate osteoclast 
precursors from the circulating monocyte–macrophage lineage9, 
infiltration of the bone lining cell layer, and fusion of the 
mononuclear cells to form multinucleated preosteoclasts (Figure 
3). The pre-osteoclasts attach themselves to the bone matrix 
creating an annular sealing zone. In forming the seal, the osteoclast 
creates the bone-resorbing compartment, a unique 
microenvironment, between itself and the bone matrix. As 
described above, osteoclast formation, activation, and activity are 
all regulated by local cytokines such as RANKL, but also by  
colony-stimulating factors (CSFs), interleukins-1 and -6 and 
systemic hormones such as PTH, 1,25-dihydroxyvitamin D3, and 
calcitonin
9-11
. During the resorption phase of the cycle, specific 
types of proton pumps in the osteoclast membrane transfer protons 
to the resorbing compartment considerably lowering its pH. 
Acidification of the resorbing compartment is accompanied by 
secretion of a number of lysosomal enzymes, such as tartrate-
resistant acid phosphatase (TRAcP) and cathepsin K, as well as 
matrix metalloproteases including MMP-9 (collagenase)
12
.  
Figure 3. Sequence of the remodelling process. Note that bone is always 
covered by cells, which are lining cells during quiescent phases. 
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The acidic solution, containing enzymes that are most active at low 
pH, effectively dissolves and digests the mineral and organic 
phases of the matrix, creating saucer-shaped resorption cavities 
(Howship’s lacunae) on the surface of the bone13. The resorption 
phase ends with osteoclast apoptosis
14
 and is followed by reversal. 
During reversal, the resorption lacuna is populated by mononuclear 
cells, including monocytes, osteocytes that have been liberated 
from the bone by osteoclasts, and pre-osteoblasts that are being 
recruited to begin the formation phase of the cycle
15
. It is during 
the reversal phase that all-important coupling signals are sent out 
to recruit osteoblasts into the resorption cavities to replace the bone 
that has been removed. Without an efficient coupling mechanism, 
each remodelling transaction would result in net loss of bone. 
Formation is a two-step process in which the osteoblasts initially 
synthesize the organic matrix and then regulate its mineralization. 
Once the collagenous organic matrix is secreted, the osteoblasts 
trigger mineralization by releasing small, membrane-bound 
vesicles, called matrix vesicles, that establish suitable conditions 
for initial mineral deposition by concentrating calcium and 
phosphate ions and enzymatically degrading inhibitors of 
mineralization, such as pyrophosphate and proteoglycans that are 
present in the extracellular matrix
16
. As bone formation continues, 
osteoblasts become entombed in the matrix as osteocytes. Each 
osteocyte becomes part of a large, 3D, functional syncitium, which 
can “sense” a change in the mechanical properties of the 
surrounding bone and transmit this information to the cells on the 
surface to initiate or regulate bone remodelling when necessary. 
The net result of each remodelling cycle is the production of a new 
osteon in the cortical bone and the replacement of trabeculae in the 
cancellous bone. Note that the process of bone remodeling is 
essentially identical in cancellous and cortical bone. The difference 
between the volume of bone removed by the osteoclasts and that 
replaced by the osteoblasts is referred to as the “bone balance”17. 
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2.2 Bone sarcoma: Osteosarcoma 
  
Clinical aspects of osteosarcoma 
Osteosarcoma is the most common primary malignant bone tumour 
in children and adolescents. Children younger than 5 years are 
rarely affected; after age 5, the incidence increases with a peak at 
age 15 years. A second peak occurs in the sixth to seventh decade. 
This second peak has been associated with Paget disease and prior 
radiation therapy, although one-half of older osteosarcoma patients 
have neither condition
18,19
. The adolescent peak occurs at a 
younger age in girls (13 years) compared with boys (15–17 years), 
and this corresponds with the age of greatest bone growth. More 
than 50% of these tumours arise from the long bones around the 
knee and distal femur, followed by the proximal tibia
20
. 
Chemotherapy has played a role in the increased overall survival 
obtained through different clinical trials over the last decades 
leading to dramatic prognostic improvements in young patients 
with localized extremity disease, with relapse-free survival rates of 
approximately 50% to 80%
21
. Metastases at diagnosis are seen in 
20% to 25% of patients with OS, with the lung being the most 
common site. Among patients with nonmetastatic disease at 
diagnosis, 20% to 25% will relapse, usually in the lungs. For 
patients with localized tumours, prognosis is better, with an overall 
event-free survival of 60% to 70%. This survival remains at about 
20% to 30% for patients with metastatic disease at diagnosis. In 
this group, the prognosis seems to be determined by the site, the 
number of metastases, and their surgical resectability. 
The most common clinical presentation of osteosarcoma is pain 
that becomes continuous and severe with time. This pain is often 
attributed to recent trauma or bone growth. In some patients, a 
mass may be palpable and the progressive swelling will affect 
adjacent joints. Pathologic fractures may occur in osteosarcoma 
patients either spontaneously or as a result of minimal trauma. 
Respiratory symptoms from metastatic lung involvement is rare 
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and require extensive bilateral lung disease. The time between 
onset of symptoms and diagnosis ranges from 2 to 4 months in 
developed countries
22
. Some genetic conditions, including Li–
Fraumeni syndrome, Paget disease, and some tumours such as 
retinoblastoma, predispose to develop osteosarcoma
23
.  
Several prognostic factors affecting overall survival have been 
identified in patients with osteosarcoma, but these have not been 
helpful in identifying patients who might benefit from treatment 
intensification
24
. Some of these prognostic factors include tumour 
location, tumour size, localized versus metastatic disease, surgical 
resectability, and degree of tumour necrosis after neoadjuvant 
chemotherapy. Other possible prognostic factors identified in 
localized high-grade osteosarcoma include age at diagnosis, serum 
lactate dehydrogenase level at diagnosis, alkaline phosphatase 
level, histological subtype, and body mass index at initial 
presentation. Older patients are considered to do worse secondary 
to the increased proportion of unfavorable axial lesions with 
increasing age
24,25
.  
As regarding tumour location, axial skeleton primary tumours 
(particularly the pelvis or the spine) are associated with a worse 
prognosis related to the inability to achieve a complete surgical 
resection and maintain local control. Within an extremity, a distal 
tumour location has a more favorable prognosis than a proximal 
location, secondary to the ability to completely remove the tumour 
with negative margins. A better prognosis has been documented in 
patients with head and neck osteosarcoma when compared with 
extremity tumours, and this may be related to the relatively smaller 
size of tumours in this anatomic area and a higher proportion of 
low-grade tumours
25,25-27
. 
Procurement of adequate diagnostic pathologic specimens is key to 
determining the correct diagnosis. Once the diagnosis of high-
grade osteosarcoma is obtained, neoadjuvant multiagent 
chemotherapy based on cisplatin, methotrexate, doxorubicin, 
ifosfamide and etoposide is started
28
. Low-grade osteosarcoma is 
treated with surgery alone. After the completion of neoadjuvant 
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chemotherapy, local control with either a limb salvage procedure 
or an amputation is performed. This procedure involves both the en 
bloc resection of the tumour and the reconstruction with synthetic 
materials, biologic materials, or a combination of both. Vascular 
and nerve reconstruction, muscle flaps, and skin grafts may be 
necessary
25
. 
 
 
Molecular pathogenesis of osteosarcoma 
Several studies highlighted that defects in osteogenic 
differentiation leading to osteosarcoma development. 
Osteoblasts arise from mesenchymal stem cells (MSCs), 
undifferentiated bone marrow stromal cells with the potential to 
self-renew and proliferate into bone, muscle, tendon, and fat
29,30
. 
Milieus of endogenous and exogenous factors are involved in 
driving the osteogenic pathway from MSC to osteoblast. 
Dysregulation of these markers, or new exposure to non-native 
stimuli (e.g. pro-tumour inflammatory cytokines), causes an 
imbalance between cellular differentiation and proliferation, 
ultimately contributing to a malignant phenotype.  
There are thought to be various similarities between early 
osteoprogenitors and osteosarcoma cells, including a highly 
proliferative nature, resistance to apoptosis, and similar expression 
profiles of genes such as alkaline phosphatase (ALP). Accordingly, 
more invasive osteosarcoma cells are noted to have minimal 
expression of osteocalcin (OCN) and osteopontin (OPN), both of 
which are observed at higher levels in mature osteoblasts. 
Bone morphogenetic proteins (BMPs) represent one group of 
factors involved in osteosarcoma stimulation
31
. Normally involved 
in carrying MSCs along an osteogenic lineage, BMPs are not only 
unable to induce differentiation of osteosarcoma cells but may 
actually promote a more aggressive phenotype
32,33
. This is due to 
an intrinsic underexpression of Runx2, a transcription factor which 
usually serves as a master regulator of BMP activity by causing 
exit from the cell cycle and promoting terminal differentiation
34,35
. 
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However, RUNX2 overexpression is also correlated with poor 
prognosis of osteosarcoma tumour, indicating that its expression is 
likely tightly controlled in normal osteogenesis. 
As observed in most cancers, abnormal activity of oncogenes and 
tumour suppressors is a key molecular underpinning of 
osteosarcoma. MDM2, a protein that marks the tumour suppressor 
p53 for degradation, is amplified in at least 1 out of 10 patients
36,37
. 
Furthermore, higher co-expression levels of MDM2 and CDK4, 
which promotes cell cycle progression, can be used reliably to 
distinguish low-grade osteosarcoma from benign masses and 
correlates with further dedifferentiation into high-grade lesions
38-40
.  
Deficient tumour suppressor activity appears to play an equally 
important role as dysregulation of oncogenes in osteosarcoma 
pathogenesis. Rb, a regulator of the G1/S cell cycle transition, is 
found to be insufficient in about 70% of all sporadic cases of 
osteosarcoma, not to mention the nearly 1000-fold increased risk 
for developing osteosarcoma in individuals who inherit an 
inactivated copy of the gene
41,42
. Similarly, mutations in tumour 
suppressor p53 are commonly found in osteosarcoma cells and 
contribute to disease progression by permitting cells with damaged 
DNA repair mechanisms to evade checkpoints and apoptosis. 
Finally, inflammation and cytokine signalling have been heavily 
implicated in the tumourigenesis of osteosarcoma
43
. For example, 
transforming growth factor β (TGF-β) is linked to the 
dedifferentiation of osteosarcoma cells into cancer stem cells, a 
dynamic population associated with tumour invasion, radio- and 
chemoresistance, and poor prognosis
44
. Often found to be involved 
in autocrine signalling by cancer cells, TGF-β increases the 
migration potential of OS cells through MAPK activation
45
. 
Similarly, tumour necrosis factor α (TNF-α) is strongly correlated 
with disease spread, indeed, has been shown to induce MMP-9 in 
osteosarcoma cells and promote metastasis to lungs in vivo
46
. 
 
 
Enrica Urciuoli 
Pag 18  
 Role of bone microenvironment in osteosarcoma development. 
Increasing evidence supports that the bone microenvironment  
underlies osteosarcoma initiation and progression. Tumour cells 
may alter the surrounding stroma inducing cell modification and 
extracellular matrix alteration. In this context, many inflammatory 
mediators may influence cell proliferation and tumour 
development, and they are responsible for invasion and 
immunosuppressive signalling through the production of 
angiogenic and growth factors, chemokines, cytokines and matrix 
metalloproteinases. 
The expression of various immune mediators and modulators, as 
well as the abundance and activation state of difference cell types 
in tumour microenvironment, lead to a tumour-promoting 
condition. Since tumour cells have a genetically-unstable 
background, the various factors and cytokines released by such 
cells might lead to or maintain an altered chronic wound-healing 
environment that further perpetuates a reactive stroma, leading to 
enhanced tumour progression and even metastasis
47
. 
 
 
2.3 Extracellular Vesicles (EVs) 
 
Intercellular communication is an essential hallmark of 
multicellular organisms and can be mediated through direct cell–
cell contact or transfer of secreted molecules. In the last two 
decades, a third mechanism for intercellular communication has 
emerged that involves intercellular transfer of extracellular vesicles 
(EVs). Although the release of apoptotic bodies during apoptosis 
has been long known, the fact that also healthy cells shed vesicles 
from their plasma membrane has only recently become 
appreciated. These vesicles are generally referred to as 
microvesicles, ectosomes, shedding vesicles, or microparticles 
among others
48,49,50
. The term exosome was initially used for 
vesicles ranging from 40 to 1,000 nm that are released by a variety 
of cultured cells
51
, but the subcellular origin of these vesicles 
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remained unclear. Later, this nomenclature was adopted for 40–
100-nm vesicles released during reticulocyte differentiation as a 
consequence of multivesicular endosome (MVE) fusion with the 
plasma membrane
52
. The involvement of MVEs was demonstrated 
by the observation that fusion with the plasma membrane released 
exosomes together with previously endocytosed colloidal gold
53
. 
Several additional cell types of both hematopoietic and 
nonhematopoietic origin, such as cytotoxic T cells, platelets, mast 
cells, neurons, oligodendrocytes, Schwann cells, and intestinal 
epithelial cells, were also shown to release exosomes through 
MVE fusion with the cell surface
54,55
. Vesicles with hallmarks of 
exosomes have been isolated from diverse body fluids, including 
semen
56,57,58
, blood
59
, urine
60
, saliva
61
, breast milk
62
, amniotic 
fluid
63
, ascites fluid
64
, cerebrospinal fluid
65
, and bile
66
. Most of 
these studies attributed the isolated vesicles to exosomes because 
of their exosome-like protein contents. However, circulating 
vesicles are likely composed of both exosomes and microvesicles 
(MVs), and currently available purification methods, do not allow 
to fully discriminate between exosomes and MVs. That a single 
cell type releases both exosomes and MVs has, for example, either 
been demonstrated or suggested for platelets
67
, endothelial cells 
68
, 
and breast cancer cells
69
. Confusion on the origin and 
nomenclature of EVs has spread through the literature as well 
because vesicles with the size of exosomes that bud at the plasma 
membrane have also been called exosomes
70
. It should be noted 
that most studies have not clearly defined the origin of EVs under 
study; therefore, in this thesis we will mostly refer to EVs rather 
than MVs or exosomes. A major ongoing challenge is to establish 
methods that will allow to discriminate between exosomes and 
MVs. Differences in properties such as size, morphology, buoyant 
density, and protein composition seem insufficient for a clear 
distinction
71
. Only when we are able to interfere with the molecular 
machineries required for EV formation and cargo sequestration 
will their origins be optimally determined. 
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Isolation and characterization of EVs 
One major challenge in this field is to improve and standardize 
methods for EV isolation and analysis
72
. Currently, EVs are mostly 
isolated from the supernatants of cultured cells grown in fetal 
bovine serum depleted of EVs by performing differential 
ultracentrifugation. Next, EVs can be efficiently separated from 
nonmembranous particles, such as protein aggregates, by using 
their relatively low buoyant density
73,74,75,76
 and differences in 
floatation velocity can be used to separate differently sized classes 
of EVs
58
. Further characterization of isolated EVs requires 
complementary biochemical (immunoblotting), mass spectrometry, 
and imaging techniques, such as electron microscopy. 
Complementary to electron microscopy, nanoparticle tracking 
analysis allows determination of the size distribution of isolated 
EVs based on the Brownian motion of vesicles in suspension
77
.  
 
 
The molecular composition of EVs 
The protein content of EVs from different sources has been 
analyzed by SDS-PAGE followed by protein staining,  
immunoblotting, or proteomic analysis. Highly purified EVs 
should be devoid of pollutants, such as serum proteins and protein 
components of intracellular compartments (e.g., the endoplasmic 
reticulum or mitochondria), that are never in contact with EVs. As 
a consequence of their origin, exosomes from different cell types 
contain endosome-associated proteins (e.g.,Rab GTPase, SNAREs, 
Annexins, and flotillin), some of which are involved in MVE 
biogenesis. Membrane proteins that are known to cluster into 
microdomains at the plasma membrane or at endosomes often are 
also enriched on EVs. These include tetraspanins, a family of >30 
proteins that are composed of four transmembrane domains
78
. 
Tetraspanins such as CD63, CD81, CD82, CD53, and CD37 were 
first identified in B cell exosomes
74
.  
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A major breakthrough was the demonstration that the cargo of EVs 
included both mRNA and miRNA and that EV-associated mRNAs 
could be translated into proteins by target cells
79,80
. Later studies 
reported on the RNA contents of EV isolates from other cell 
cultures
81
 and from body fluids
82-84
. EVs with features of exosomes 
released by immune cells have been demonstrated to selectively 
incorporate miRNA that can be functionally transferred as a 
consequence of fusion with recipient cells
85,86
. Analysis of RNA 
from EVs demonstrated that, in addition to mRNA and miRNA, 
EVs also contain a large variety of other small noncoding RNA 
species, including RNA transcripts overlapping with protein 
coding regions, repeat sequences, structural RNAs, tRNA 
fragments and small interfering RNAs
87,88
. Many RNAs that were 
isolated with EVs were found to be enriched relative to the RNA 
profiles of the originating cells
79-81,88
, indicating that RNA 
molecules are selectively incorporated into EVs. Also, different 
RNA isolation methods give extensive variation in exosomal RNA 
yield and patterns
89
, and such experimental variations between 
studies, together with the lack of quantitative data, make it 
impossible to define a comparative inventory of the RNA species 
assigned to EVs so far. 
 
 
Interaction of EVs with recipient cells 
Functions of EVs in physiological and pathological processes 
depend on the ability of EVs to interact with recipient cells and to 
deliver their contents of proteins, lipids, and RNAs (Figure 4). 
The cellular and molecular basis for EV targeting is still 
undetermined, but several target cell–dependent and –conditional 
aspects are beginning to emerge. Target cell specificity for binding 
of EVs is likely to be determined by adhesion molecules, such as 
integrins, that are present in EVs. After binding to recipient cells, 
EVs may remain stably associated with the plasma membrane or 
dissociate, directly fuse with the plasma membrane, or be 
internalized through distinct endocytic pathways (Figure 4). 
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When endocytosed, EVs may subsequently fuse with the 
endosomal delimiting membrane or be targeted to lysosomes for 
degradation.  
The interest of scientists and physicians in EVs has expanded 
logarithmically over the past decade in response to the discoveries 
that EVs are not only generated in cell culture but are also 
abundantly present in body fluids, carry RNA, and show a wide 
range of regulatory functions. 
 
 
 
Figure 4. Schematic of protein and RNA transfer by EVs. Membrane-associated 
(triangles) and transmembrane proteins (rectangles) and RNAs (curved symbols) 
are selectively incorporated into MVEs budding from the plasma membrane. 
MVEs fuse with the plasma membrane to elease exosomes into the extracellular 
milieu. MVs and exosomes may dock at the plasma membrane of a target cell 
(1). Bound vesicles may either fuse directly with the plasma membrane (2) or be 
endocytosed (3). Endocytosed vesicles may then fuse with the delimiting 
membrane of an endocytic compartment (4). Both pathways result in the 
delivery of proteins and RNA into the membrane or cytosol of the target cell. 
Fusion and endocytosis are only represented for exosomal vesicles, but plasma 
membrane–derived MVs may have similar fates53. 
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As discussed, we are still at an early stage of deciphering the 
molecular mechanisms involved in EV biogenesis and recruitment 
of cargo therein. Specific knowledge of these mechanisms will 
help us to intervene with EV function in vivo, an absolute 
requirement to decipher their precise role in physiological 
processes. Also, more accurate and standardised purification 
methods are required for the implementation in a clinical setting of 
EVs as biomarkers, vaccines, or drug delivery devices
53
. 
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3. Aims  
 
 
 
 
 
The field of study based on extracellular vesicle involvement in 
cancer onset and progression is generating growing interest. Since 
there are no evidence in the literature regarding this new 
mechanism of communication in osteosarcoma cancer, the final 
aim of this thesis is to investigate the role of extracellular vesicles 
as mediators between cancer cells and resident bone cells. 
 
Therefore, our experimental plan was designed considering 
three specific aims, as follows: 
 
 To evaluate EV production by osteosarcoma cells 
 
 To assess a tumoral-like conditioning of recipient normal 
cells mediated by osteosarcoma-derived EVs 
 
 To assess the feasibility to use EVs in therapeutic 
approaches to osteosarcoma. 
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4. Results 
 
4.1 Human osteosarcoma cancer cells produce 
extracellular vesicles. 
 
To evaluate if osteosarcoma cells are able to produce extracellular 
vesicles (EVs), we used human cell lines to set the best methods 
for EV isolation and visualization. 
Given the variety of EV isolation protocols described in the 
literature
90
, we compared the effectiveness and the reproducibility 
of 3 different methods for EV collection starting from equal 
amounts of osteosarcoma cell-conditioned culture medium.   
We used osteosarcoma cell lines Saos-2 and 143B, respectively  
very low aggressive and metastatic cell lines. These cells were 
stained with two fluorescent dyes, CFSE and PKH-26, to point out 
respectively green cytoplasms and red plasma membranes, thereby 
allowing the production of CFSE
+
/PKH-26
+
 EVs in the 
conditioned media (Figure 5). 
 
 
Figure 5. CFSE/PKH-26 staining of osteosarcoma cells 
 
 Twenty-four hour conditioned medium was split in 3 equal parts 
and then processed by using 3 different methods: i) 
Ultracentrifugation, ii) Amicon Ultra Centrifugal filter and iii) 
ExoQuick™, a commercial polymer. 
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Purified EVs were analysed by using fluorescence-activated cell 
sorting (FACS) for the amount of CFSE
+
/PKH-26
+
 EVs.  
We used beads with a known size of 1.3, 0.7 and 0.5μm to create a 
gate (size < 1μm) in which we expected to find EVs. Next, we used 
the fluorescent signal of CFSE
+ 
EVs to distinguish these 
nanoparticles from background noise (Figure 6A), then we 
analyzed the amount of double positive CFSE
+
/PKH-26
+
 EVs 
(Figure 6B).  
Moreover, to be sure to compare equal volumes, we added the 
same number of CountBright™ Absolute Counting Beads to each 
sample, so, by maintaining fixed the number of beads at 5000, we 
defined the volume of 5μL for analysis. In this way we were able 
to count EVs (Figure 6C).  
Once set the experimental procedure, we compared the amount of 
EVs obtained by using the aforementioned methods of isolation. In 
our condition, we found ExoQuick™ solution to be the best EV 
isolation method in terms of reproducibility (Figure 6D), while the 
other methods showed great variability of the results obtained in 
the triplicated experiment. As regards the comparison between the 
EV production by the two osteosarcoma cell lines, only 
ExoQuick™ procedure led to isolate a comparable amount of 
vesicles, result confirmed at a later time by other methods (Figure 
9). 
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Figure 6. (A) Nanobeads dot-plot visualization used to create a gate of size 
<1μm for EVs. SSC, scattered light; FSC, forward-scattered light. (B) Dot-plot 
analysis showing purified CFSE
+
/PKH-26
+
 EVs  by using fluorescence-activated 
cell sorting (FACS). (C) Dot-plot analysis showing CountBright Beads gate, 
indicated as P1 and representative table of EV count by maintaining fixed at 
5000 the number of beads. (D) Dot-plot analysis showing EVs collected using 
the described methods. 
 
In order to visualize EV release by the plasma membrane, we used  
three different osteosarcoma cancer cell lines: Saos-2, HOS and 
143B, respectively low aggressive, non-metastatic and high 
metastatic cells. These cells were stained with rhodamine-
coniugated phalloidin to detect F-actin. As reported by Antonyak 
and co-workers on breast cancer cells
91
, also in our condition 
phalloidin staining revealed bubble-like structures on the surface of 
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osteosarcoma cells, resembling EVs about to be released (Figure 
7). 
 
 
 
 
Figure 7. Confocal microscopy analysis of the indicated osteosarcoma cells 
stained with rhodamine-coniugated phalloidin (grey) and Hoechst (blue) to 
visualize EVs on plasma membrane (white arrows). Z-reconstructions are 
imported into LASX 3D Analysis (Leica Microsystems) software to obtain the 
three-dimensional surface rendering. 
 
In order to confirm EV production by using a different method, we 
exploited CD63 expression, that is considered an EV marker
92,93
. 
As demonstrated by western blot analysis (Figure 8A),  
osteosarcoma-derived EVs express the CD63 marker, as also 
confirmed by FACS analysis assessing the PKH-26
+
/CD63
+
 EVs 
(Figure 8B). Our results showed a comparable amount of both 
CD63 revealed by western blot and CD63
+
 percentage of EVs 
produced by osteosarcoma cell lines.  
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Figure 8. (A) WB analysis of CD63 in osteosarcoma-derived EVs. (B) Dot-plot 
analysis showing PKH-26
+
/CD63
+
 EVs.  
 
4.2 Osteosarcoma cell lines with different aggressiveness 
produce similar quantities of EVs. 
 
We compared the amount of EVs produced by the different 
osteosarcoma cancer cell lines: Saos-2, HOS and 143B.Once 
isolated, EVs were quantified by using four different methods: 
 CFSE+/PKH-26+ EV quantification by FACS analysis 
 EXOCET- quantification assay kit to assess the number of 
EVs, 
 Tunable Resistive Pulse Sensing (TRPS) Technology by 
Izon Science to obtain the number of particles/ml, 
Enrica Urciuoli 
Pag 30  
 BCA assay for protein quantification.   
 
 
 
Figure 9.  (A) Quantification of extracellular vesicles collected from 24 hour-
conditioned media of the osteosarcoma cell lines by using the indicated 
methods. (B) Quantification of the EV protein content by BCA assay. 
As shown in Figure 9, we demonstrate that these three cell lines, 
although with a different aggressiveness, produce comparable 
amount of EVs, unlike other cancer cells described in the literature. 
This unexpected result prompted us to study the EV’s cargo to 
explore the possibility of a different mRNA or protein content 
conveyed in the EVs derived from the three osteosarcoma cell 
lines. 
 
 
4.3 Effects mediated by osteosarcoma-derived EVs on 
normal NIH3T3 cells. 
 
CFSE
+
/PKH-26
+
 EVs fuse into NIH3T3 target cells. 
Starting from data in the literature concerning the capability of 
tumour-derived EVs to induce tumour phenotypes in normal 
cells
91
, we investigated whether also osteosarcoma-derived EVs 
can be able to transform normal recipient cells. To this aim, we 
collected CFSE
+
/PKH-26
+
 EVs from Saos-2, HOS and 143B cells 
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as previously described and used them to treat NIH3T3 murine 
fibroblasts. CFSE
+
/PKH-26
+
 EVs isolated from osteosarcoma cell 
lines medium merged recipient fibroblasts, leading to CFSE
+
/PKH-
26
+ 
NIH3T3 cells, as assessed by fluorescent microscopy analysis 
(Figure 10A).  EVs derived from different cell lines have the 
capability to fuse into target cells with a comparable effectiveness, 
as indicated by the percentage (about 80% of fusion) of 
CFSE
+
/PKH-26
+ 
NIH3T3 cells shown in Figure 10B. 
 
 
 
 
Figure 10: (A) Confocal microscopy analysis of NIH3T3 treated for 6 hours 
with CFSE
+
/PKH-26
+
 EVs. Pictures show the resulted CFSE
+ 
and PKH-26
+ 
recipient cells as proof of EVs fusion. (B) Quantification of CFSE
+
/PKH-26
+ 
NIH3T3 cell percentage following the fusion with CFSE
+
/PKH-26
+ 
EVs. 
Original magnification 60x.  
These results were confirmed by FACS analysis performed on 
NIH3T3 treated for 6 hours with CFSE
+
/PKH-26
+ 
 osteosarcoma-
derived EVs, as shown Figure 11. 
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Figure 11. Dot-plot analysis of CFSE
+
/PKH-26
+ 
NIH3T3 after fusion with 
CFSE
+
/PKH-26
+  
osteosarcoma-derived EVs. 
Next, we used the aforementioned CD63 marker to monitor the 
fusion of tumour EVs into normal cells. To do this, we treated 
murine fibroblasts NIH3T3 for 72 hours with human osteosarcoma 
cell-derived EVs and then investigated the presence of human 
CD63 in the recipient murine fibroblasts. The specificity of anti-
human CD63 antibody was confirmed by comparing the negative 
staining of untreated  murine NIH3T3 cells to the 65% of CD63 
positivity of untreated human fibroblasts. The FACS analysis 
confirmed the presence of human CD63 in treated NIH3T3, 
although with a variable efficiency of fusion, resulted at a higher 
percentages in the treatments with 143B-derived EVs (53.6%) than 
the treatments with the other cell line EVs (Figure 12). 
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Figure 12. Dot-plot analysis of  CD63
+
 cells. 
The treatment with osteosarcoma derived-EVs improves NIH3T3 
proliferation and survival in low-serum conditions. 
To investigate which kind of effect could be induced by the 
treatment of recipient normal cells with osteosarcoma derived-
EVs, NIH3T3 cells were treated with a single shot of tumour-
derived  EVs and, after 72 hours, evaluated for proliferation by cell 
count. As shown in Figure 13, we obtained a statistically relevant 
result following the  treatment with 143B derived-EVs. 
Enrica Urciuoli 
Pag 34  
 
Figure 13. Cell count of NIH3T3 treated with osteosarcoma-EVs. *p < 0.05 
Starting from this result on proliferation, we examined the effects 
of EV-mediated treatment on some of the most relevant signalling 
pathways involved in the regulation of cell proliferation. We 
performed western blot analysis for activated AKT and ERK 
proteins in NIH3T3 treated with osteosarcoma-derived EVs. As 
shown in Figure 14, an increased expression of phospho-AKT and 
phospho-ERK was found, especially in the treatment with HOS- 
and 143B-derived EVs.  
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Figure 14. Representative Western blot analysis of phosphorylated AKT 
(pAKT), total AKT, phosphorylated ERK (pERK) and total ERK in NIH3T3 
treated with osteosarcoma-derived EVs, normalized versus housekeeping 
GAPDH. Untreated NIH3T3 were used as control.  
To further investigate the effects mediated by tumoral EV 
treatment on NIH3T3, we performed experiments in starvation 
conditions which, in the long run, are known to reduce 
proliferation (2% FBS condition) or induce cell death (BSA 
condition) in normal fibroblasts. As shown in Figure 15, the 
treatment of starved NIH3T3 with osteosarcoma derived-EVs for 
72h induced an increase of cell count, highlighting the capability of 
tumoral EVs to induce survival in NIH3T3 that, usually, are not 
able to survive in low serum conditions.  
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Figure 15. Cell count of NIH3T3 treated with osteosarcoma derived-EVs in 
starvation conditions. * p <0.05, **p <0.01 versus the relative control.  
Moreover, to better understand these effects on NIH3T3 survival, 
we evaluated the percentage of apoptotic fibroblasts after the EV-
treatment in BSA condition, by using Annexin V assay. As 
reported in Figure 16, the percentage of live NIH3T3 cells 
increased after the treatment with osteosarcoma-derived EVs from 
76% in control BSA condition to 91-93% in treated cells, while the 
percentage of apoptotic fibroblasts drastically decreased, showing 
a behaviour comparable to NIH3T3 cultured in canonical condition 
(10% FBS). Beside the analysis of apoptosis pattern, we studied 
the cell cycle rate in starvation condition, finding an increased of 
NIH3T3 in G0/G1 phase following EV treatment (Figure 17), 
thereby indicating that the treatment with osteosarcoma-derived 
EVs maintained NIH3T3 alive, but blocked in G0/G1 stage.  
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Figure 16. Annexin V assay analysis of NIH3T3 treated with osteosarcoma-
derived EVs in BSA condition, compared to canonical culture condition (10% 
FBS). 
 
 
Figure 17. Cell cycle analysis of NIH3T3 treated with osteosarcoma-derived 
EVs in BSA condition, compared to canonical culture condition (10% FBS). 
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To exclude the possibility of any aspecific effect mediated by 
extracellular vesicles, and in order to confirm the transforming 
power of osteosarcoma derived-EVs, we performed the same kind 
of experiments by using EVs isolated from normal cells, as 
NIH3T3, human Mesenchymal Stromal Cells (MSC) and human 
osteoblasts (HOB). After the treatment, NIH3T3 showed no 
difference in terms of proliferation or survival in comparison to  
controls (Figure 18). 
 
Figure 18. Cell count of NIH3T3 treated with EVs derived from normal cells. 
 
NIH3T3 treated with osteosarcoma-derived EVs exhibited 
enhanced migration capability and an acquired anchorage-
independent growth.  
To gain insight into the involvement of osteosarcoma-derived EVs 
in the tumour-like transformation of normal cells, we assessed the 
capability of EV-treated NIH3T3 cells to migrate and to grow in  
anchorage-independent  condition. To this aim, NIH3T3 cells were 
treated with tumoral EVs for 5 hours and then evaluated for their 
migration capability by wound healing assay, showing a higher 
area covered by cells if compared to the control, as indicated by the 
reduction of the wound size (Figure 19). Moreover, we exploited 
the inability of control NIH3T3 fibroblasts to form colonies in soft 
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agar to demonstrate that the treatment with osteosarcoma-derived 
EVs induced on these cells the acquired capability to grow under 
anchorage-independent conditions (Figure 20). Thus, the EV-
mediated transfer of cancer cell material to normal cells is indeed 
capable of endowing normal cells with the features of tumorigenic 
transformation. 
 
 
 
Figure 19. Representative pictures and the relative quantification graph of the 
wound size in a wound healing assay performed on NIH3T3 treated with 
osteosarcoma-derived EVs. Original magnification 20x. 
 **p <0.01, *** p <0.0001 
 
 
 
 
 
Figure 20. Representative images and quantitative analysis of colony formation 
in the anchorage-independent growth assay. Original magnification 10x. 
 **p <0.01, *** p <0.0001 
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Osteosarcoma-derived EVs transfer osteogenic and tumour 
markers into recipient NIH3T3 cells. 
To better define the effects of tumour-derived EVs, we studied the 
capability of EVs to transport their mRNA content into recipient 
cells. In our system we used human osteosarcoma-derived EVs to 
treat murine normal fibroblasts allowing us to analyse the presence 
of human mRNA in murine fibroblasts. Moreover, given that 
osteosarcoma arises from transformed cells of the osteoblastic 
lineage,  we evaluated the expression of osteoblastic and 
tumorigenic mRNA. As reported in Figure 21, following the 
treatment with EVs, murine NIH3T3 expressed human and murine 
ALkalin Phosphatase (ALP) mRNA, a specific marker of 
osteoblastic differentiation as well as the murine isoform of matrix 
metallopeptidase 9 (MMP-9) and the human isoform of tumor 
necrosis factor-α (TNF-α), well known markers of tumorigenesis. 
 
 
Figure 21. mRNA expression in NIH3T3 treated with osteosarcoma-derived 
EVs. 
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4.4 Effects of osteosarcoma-derived EVs on normal 
human bone cells. 
 
Basing on the tumoral transformation  resulted by treating NIH3T3 
fibroblast with osteosarcoma-derived EVs, we decided to study the 
effects of osteosarcoma-derived EVs on bone cells. 
To this aim, we performed experiments using these extracellular 
vesicles to treat the bone microenvironment cells: mesenchymal 
stromal cells (as osteoblast progenitors), primary human 
osteoblasts and monocytes (as osteoclast precursors). 
 
 
Effects of osteosarcoma-derived EVs in Mesenchymal Stromal 
Cells (MSCs). 
We collected osteosarcoma-derived EVs as previously described 
and used them to treat healthy donor-derived MSCs. Twenty-four 
hour treatment induced no differences in proliferation, assessed by 
cell count (Figure 22). 
 
 
 
Figure 22. Cell count of MSCs treated for 24h with the indicated osteosarcoma-
derived EVs.  
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To study more in detail this effect, we treated MSCs with 
osteosarcoma-derived EVs for 3 weeks and then assessed their 
positivity for osteoblast markers. Despite the absence of osteogenic 
medium, indispensable to trigger osteoblastic differentiation, we 
surprisingly found a slight induction of ALP following the 
treatment with Saos2-derived EVs, as well as a relevant induction 
of mineralization assessed by Alizarin Red staining, especially 
following the treatment with Saos2- and HOS-derived EVs 
(Figure 23).   
In order to verify whether this effect could be enhanced by the 
induction of osteoblastic differentiation, we treated MSCs with 
osteogenic medium and with osteosarcoma-derived EVs. To avoid 
the achievement of a plateau condition, this experiment lasted 10 
days, instead of the canonical 21 days of treatment in osteogenic 
medium. At the end of this experiment,  we found once again both 
an increase of ALP and a massive induction of mineralized noduli 
stained by Alizarin Red in Saos2-derived EV treatment (Figure 
24). 
 
 
 
Figure 23. Representative pictures of ALkaline Phosphatase (ALP) and Alizarin 
red staining of MSCs treated for 3 weeks with medium supplemented with 10% 
FBS and the indicated osteosarcoma-derived EVs. Original magnification 20x. 
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Figure 24. Representative pictures of ALkaline Phosphatase (ALP) and Alizarin 
red staining of MSCs treated for 10 days with osteogenic medium and the 
indicated osteosarcoma-derived EVs. Original magnification 20x. 
 
Effects of osteosarcoma-derived EVs on human osteoblasts 
(hOBs). 
As regards osteoblast cells, we performed the same experiments 
described above, by treating human primary osteoblasts with 
osteosarcoma-derived EVs. After 24h of treatment, hOBs showed 
not relevant modulation in proliferation and differentiation (Figure 
25). 
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Figure 25. (A) Cell count of osteoblasts treated for 24h with the indicated 
osteosarcoma-derived EVs. (B) Quantification of hOB treated for 72 hours with 
medium supplemented with 10% FBS and the indicated osteosarcoma-derived 
EVs 
Moreover, in order to  further investigate the ability of the tumour- 
EVs to transform normal cells, we evaluated tumour-like 
phenotypes in EV-treated osteoblasts. To this aim, as described for 
NIH3T3 cells, normal osteoblasts were treated with osteosarcoma-
derived EVs for 5 hours and then evaluated for their capability to 
migrate by a wound healing assay. Our results showed a 
significantly improved migration demonstrated by the reduction of 
the wound size (Figure 26). Next, we investigated the anchorage-
independent growth of EV-treated osteoblasts finding, also in this 
condition, an acquired capability to form colonies in soft agar 
(Figure 27). 
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Figure 26. Representative pictures and the relative quantification graph of the 
wound size in a wound healing assay performed on hOB treated with 
osteosarcoma-derived EVs. Original magnification 20x.  *** p <0.0001  
 
 
 
Figure 27. Representative images and quantitative analysis of colony formation 
in the anchorage-independent growth assay. Original magnification 10x. 
 **p <0.01, *** p <0.0001 
 
 
Finally, in order to investigate the effects caused by osteosarcoma-
derived EVs on hOBs, we analysed the transcriptional levels of 
osteoblast differentiation markers, such as ALP, COLL1A2 and 
RUNX2, as well as genes involved in the tumourigenic 
transformation, as  TNF-α, TGF-β and IL6. As shown in Figure 
28, our findings evidenced that in particular RUNX2 and TNF-α 
mRNA were increased in osteoblasts treated with osteosarcoma-
derived EVs.  
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Figure 28. mRNA expression levels in human osteoblasts treated with 
osteosarcoma-derived EVs. 
 
 
Effects of osteosarcoma-derived EVs on human monocytes. 
As regarding the osteoclast precursors, we treated healthy donor-
derived monocytes with canonical MCSF (20ng/ml) as control 
condition of proliferation and with osteosarcoma-derived EVs for 
24 hours. Figure 29 highlighted a significant increase in monocyte 
proliferation treated with HOS-derived EVs compared to control. 
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Figure 29. Cell count of monocytes treated for 24h with MCSF (ctl) or with 
indicated osteosarcoma-derived EVs. *** p <0.0001 
 
 Next, in order to assess any effect on osteoclastogenesis, we 
treated healthy donor-derived monocytes for 2 weeks with the 
canonical M-CSF (20ng/ml) and RANKL (30ng/ml) treatment as 
control condition and with osteosarcoma-derived EVs. As shown 
in Figure 30, osteosarcoma-derived EV alone resulted able to 
induce the formation of TRAP
+
 multinucleated osteoclasts, 
although in a lower amount than canonical treatment.  
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Figure 30. Representative pictures of TRAP staining (upper panels) and the 
relative count (lower panel) of TRAP
+
 Osteoclasts obtained by treating 
monocytes with canonical treatment (MCSF+RANKL) or with the indicated 
osteosarcoma-derived EVs. Original magnification 20x. 
* vs  MCSF. * p<0.05, **p <0.01. 
 
 
In order to explain the induction of monocyte proliferation and 
differentiation observed following EV treatments, we assessed the 
presence of osteoclast-stimulating factors (RANK, RANKL and 
M-CSF) in osteosarcoma cell lines and derived EVs, by FACS 
analysis.  
All cell lines expressed high levels of these cytokines, in particular 
the high metastatic 143B cells. As regarding the corresponding 
EVs, we found them positive for RANK and RANKL, in particular 
HOS- and 143B-derived vesicles. Only HOS-derived EVs showed 
high M-CSF expression level (Figures 31-32). 
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Figure 31. Analysis of MCSF
+
/RANK
+
/RANKL
+ 
EVs percentage. 
 
 
 
Figure 32. Dot-plots analysis showing RANK/RANKL/MCSF expression in 
osteosarcoma-derived EVs.  
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4.5 To use EVs as prognostic/diagnostic markers.  
 
Once demonstrated some features of this new type of cell 
communication mediated by EVs, we focused our attention on the 
feasibility to use these vesicles as prognostic markers in 
osteosarcoma. 
GD2 ganglioside is a well known marker of neuroblastoma
94,95
, it 
has been described as a component of neuroblastoma-derived EV 
cargo
96
 and in a recent study it was reported that GD2 was stably 
expressed in osteosarcoma  cells
97
.  
So we studied the expression of surface protein GD2 ganglioside in 
our nanoparticles. To this aim, we performed a cytofluorimetric 
assay on osteosarcoma cell lines and their derived EVs by using 
anti-human GD2-PE antibody. As reported in Figure 33, 
osteosarcoma cell lines with increasing aggressiveness expressed 
increasing levels of GD2 on their surface, and the same result was 
also obtained when we analyzed osteosarcoma-derived EVs.  
 
 
Figure 33. Dot-plot analysis showing GD2
+
 osteosarcoma cell lines (left panel) 
and GD2
+ 
osteosarcoma-derived EVs (right panel). 
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4.6 To inhibit EV production in osteosarcoma cells.  
 
We investigated the capability to counteract EV production by 
acting on remodelling of actin cytoskeleton. In particular, we 
focused our attention on Y-27632, an inhibitor of Rho-associated 
coiled–coil containing protein kinase (ROCK). To test the 
reduction of EV production as consequence of Y-27632 treatment, 
we evaluated the amount of EV by using EXOCET method, as 
described before. In Figure 34 is shown that Y-27632 treatment 
was able to reduce significantly the amount of osteosarcoma EVs 
and in particular the major effect was obtained in HOS cell lines. 
 
 
Figure 34. EXOCET quantification of osteosarcoma-derived EVs with or 
without the treatment with Y-27632.  *** p <0.0001 
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5. Discussion 
 
Osteosarcoma is the most common primary malignant bone tumour 
in children and adolescents. With one of the lowest survival rates 
among paediatric cancers, Osteosarcoma imparts a 5-year 
survivorship of 70% in patients treated for localized disease, but 
only 30% when metastases are present. Therefore, there is a critical 
need to better understand the underlying mechanisms of disease 
development and progression. 
Cell can communicate with neighbouring cells or with distant cells 
through the secretion of extracellular vesicles (EVs). The release of 
EVs from different types of high-grade or aggressive forms of 
human cancer cells into their surroundings is becoming 
increasingly recognized as a feature of tumour biology
96,98,99
.  
Hence, as the first aim of this study, we pointed to investigate the 
ability of human osteosarcoma cell lines to produce EVs. The 
isolation of EVs is a crucial point for researcher that study this 
topic because there is a great variety of methods and each presents 
some limitations. Moreover, high sensitive equipment is needed to 
work with EVs, because of their very little size. Therefore, taking 
into consideration these issues, the first part of this study has been 
spent to define the best methods for EV isolation and visualization 
in dependence on our experimental conditions. First of all, we 
compared 3 of the most used methods to isolate EVs: the 
ultracentrifuge, Amicon filters and the ExoQuick™ polymer.  
In order to compare the amount of EVs isolated by each method, 
we needed to visualize and, if possible, to count these particles by 
fluorescence-activated cell sorting (FACS) analysis. Since this 
instrument is routinely used to analyse cells, we adapted our FACS 
protocol by introducing the following expedients:  
1) fluorescence dyes: we used CFSE and PKH-26 dyes to stain 
osteosarcoma cells, and obtain CFSE
+
/PKH-26
+
 EVs in the 
conditioned media. In this way, we were able to discriminate 
fluorescent EVs from background noise by FACS analysis.  
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2) beads with known size: by using 0.5, 0.7 and 1.3 µm beads, we 
were able to define the gate in which we expected to find 
fluorescent EVs by FACS analysis. 
3) CountBright beads: by adding these beads to each sample, we 
knew exactly the volume analysed in each condition, allowing us 
to define the concentration of EVs by FACS analysis.  
Once set this procedure, we compared the amount of EVs produced 
by 2 osteosarcoma cell lines and isolated by using ultracentrifuge, 
Amicon filters and the ExoQuick™. Our results prompted us to 
choose  ExoQuick™ as unique isolation method for conducting our 
experimental project. Indeed, we demonstrated that this polymer 
guaranteed not only the higher amount of isolated vesicles, but also 
the best reproducible results.   
Once verified that osteosarcoma cells produce EVs, the second 
step was to obtain EV visualization and, at the same time, to 
quantify them. Basing on Antonyak et al. work, we exploited 
phalloidin staining to unveil EVs on the plasma membrane of 
osteosarcoma cells. By three-dimensional reconstruction of 
confocal microscopy z-stack series, we demonstrated that 
osteosarcoma cells produced EVs and, as expected, their release 
occurred at the apical portion of the plasma.  
Next, we intended to compare EV production of three 
osteosarcoma cell lines with increasing aggressiveness. Indeed, as 
reported for other types of cancers, we expected to find a 
correlation between osteosarcoma aggressiveness and the amount 
of produced EVs. As regards EV quantification, once again we had 
to deal with the different methods and protocols described in the 
literature. First of all, we assessed the expression of CD63, a 
specific EV marker, in osteosarcoma EVs, by FACS analysis, and 
in their protein lysates, by western blot. Our results suggest that, in 
our experimental conditions, CD63 analysis of osteosarcoma-
derived EVs is not a useful tool, because of the incomplete staining 
of EV population, obtained by PKH-26 dye. Indeed, less than 50% 
of total EVs resulted CD63
+
, prompting us to identify other 
methods to quantify tumoral EVs.  
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To this aim, we compared EV production by using other methods 
well known in literature, as the count of CFSE
+
/PKH-26
+
 EVs by 
FACS analysis, EXOCET quantification assay, the TRPS analysis 
and the quantification of total proteins conveyed by EVs. By using 
these methods we ascertained that the amount of total EV produced 
by each osteosarcoma cell line was comparable, unlike our 
expectations. Moreover, the TRPS analysis performed by Izon 
Science attested the range sizes of our osteosarcoma nanoparticles 
at 50-200nm, confirming their nature of EVs. 
In order to further characterize EVs, we assessed the effects of 
tumoral EVs on recipient cells. Generally, tumour cells may alter 
the surrounding stroma inducing cell modification and, recently, it  
has been also described for other tumour cells the capability of 
their EVs to induce transformation in target cells
91
. We chose a 
murine fibroblast cell line, NIH3T3, as recipient cells to study the 
tumoral effects of osteosarcoma-derived EVs in a context different 
from the bone tissue in which this tumour develops. We obtained 
the first evidence of the osteosarcoma-derived EV capability to 
fuse into target cells by observing CFSE
+
/PKH-26
+
 NIH3T3 after 
the treatment with CFSE
+
/PKH-26
+
 EVs, as assessed by both 
confocal microscopy and FACS analysis. Moreover, although the 
inadequate result obtained with CD63 staining as quantification 
tool, we exploited human CD63
+
 EVs produced by osteosarcoma 
cells to investigate their fusion on mouse target cells, thereby 
evaluating the transfer of human material from osteosarcoma cells 
to murine fibroblast NIH3T3. To test this hypothesis, we treated 
murine NIH3T3 cells with osteosarcoma-derived EVs and then 
assessed the presence of human CD63 by FACS analysis. 
Although the production of CD63
+
 vesicles has resulted 
comparable among the three cell lines, we observed a variable 
efficiency of fusion, resulted at the highest percentages in the 
treatments with 143B-derived EVs, demonstrating that this high 
metastatic osteosarcoma cell line produced EVs able to fuse in to 
target cells more efficiently than less aggressive cell lines HOS and 
Saos-2. Moreover, this finding suggests that the pattern of effects 
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mediated by these vesicles cannot be referred in general terms to 
"osteosarcoma" cells, but reflects the specific features of the cell of 
origin. 
Next, we evaluated transformation towards tumoral-like phenotype 
in EV-treated NIH3T3. To this aim, as a proof of concept of the 
transforming power of these vesicles, we decided to apply an acute 
stimulation, considering just one treatment with osteosarcoma-
derived EVs. By using canonical culture condition (medium 
supplemented with 10% FBS), the treatment of NIH3T3 with 
osteosarcoma-derived EVs showed an increase in their 
proliferation and in the activation of key pathways involved in cell 
proliferation, especially following the treatment with 143B-derived 
EVs. This result once again indicates a differential pattern of 
effects mediated by EVs deriving from different osteosarcoma cell 
lines, in particular related to their aggressiveness. When we 
cultured normal NIH3T3 in low-serum condition (medium 
supplemented with 2% FBS) or starvation condition (medium 
supplemented with 0.25% BSA), we found as expected a decrease 
of proliferation and an induction of apoptosis, respectively. 
Surprisingly, the treatment with osteosarcoma-derived EVs rescued 
fibroblast capability to survive in both types of media. In 
particular, in BSA condition, we counted a higher number of 
NIH3T3 that, as demonstrated with Annexin V assay and cell cycle 
analysis, resulted to be Annexin negative and blocked in G0/G1 
phase. So, after the treatment with osteosarcoma-derived EVs 
NIH3T3 were alive and survivor, although not proliferating, 
despite the starvation condition. To confirm this finding and 
exclude the possibility of any aspecific effect, we treated NIH3T3 
with EVs isolated from normal cells, as NIH3T3 themselves, 
human Mesenchymal Stromal Cells (MSC) and human osteoblasts 
(HOB). Indeed, we found no changes in proliferation rate of 
NIH3T3 so treated.  
Basing on these results, we decided to study other features 
regarding the tumoral transformation of normal NIH3T3. 
Interestingly, osteosarcoma-derived EVs have been demonstrated 
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to induce in recipient NIH3T3 an increase of migration and the 
acquired capability to growth in an anchorage-independent 
manner. Also in these conditions, we found that greater effects 
were induced by 143B-derived EVs, confirming that the signals 
conveyed by these tumoral vesicles reflect specific features of the 
cell of origin, which are known to have a high migration rate.  
Moreover, since our preliminary evidence suggested the carriage of 
human material in murine fibroblasts, as described before, we 
analysed the expression of human and murine osteoblastic and 
tumorigenic mRNAs in NIH3T3 after the EV treatment. Murine 
NIH3T3 expressed human and murine ALkalin Phosphatase (ALP) 
mRNA, a specific marker of osteoblastic differentiation and, at the 
same time, these cells expressed murine isoform of matrix 
metallopeptidase 9 (MMP-9) and the human isoform of tumor 
necrosis factor-α (TNF-α), that are well known markers of 
tumorigenesis. The presence of human mRNA in murine 
fibroblasts confirmed the ability of tumoral EVs to transfer 
material of cell of origin (exogenous). But, more intriguing, the  
endogenous expression of markers of osteoblastic lineage or 
tumoral cells suggests that osteosarcoma-derived EVs convey 
within them some transcription factors or upstream signals able to 
induce the transcription of those specific markers. Taken together, 
these findings strongly support the great transforming power that 
these particles have.  
These data prompted us to study the effects mediated by 
osteosarcoma-derived EVs on cells of the bone microenvironment, 
in which the tumour develops and likely establishes a crosstalk 
with resident cells. It is known that osteosarcoma can form both 
osteoblastic and osteolytic lesions, due to an increase of 
osteoblastic and osteoclastic activity, respectively. So, to this aim, 
we assessed the effect of tumoral vesicles on human osteoblasts 
(hOBs), Mesenchymal Stromal Cells (MSC) as osteoblast 
precursors, and human healthy-donor monocytes, as osteoclasts 
precursors. Our  results on MSC showed that the treatment with 
osteosarcoma-derived EVs in normal culture conditions did not 
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affect the proliferation, but induced a slight increased in 
differentiation, as demonstrated by the presence of ALP
+
 and 
Alizarin red
+
 MSCs following Saos-2-derived EVs. These results 
prompted us to evaluate EV-treatment effects upon the induction of 
osteogenic differentiation. Indeed, MSCs, treated with osteogenic 
medium for 10 days, despite the canonical 3 week-treatment, and 
with tumoral EVs showed a higher differentiation toward the 
osteoblastic lineage, becoming ALP
+
 as well as Alizarin Red
+
 
especially in Saos2-derived EV treatment, compared to the control. 
In order to avoid a plateau effect due to the canonical treatment 
with the osteogenic medium, we chose to reduce the duration of 
the protocol to better appreciate any effect mediated by EV 
treatment. 
These findings suggest that osteosarcoma cancer cells producing 
EVs in the bone microenvironment induce the differentiation of 
osteoblast precursors, likely leading to the formation of aberrant 
tumoral bone matrix. 
As regarding the effects on differentiated osteoblasts, following the 
treatment with osteosarcoma-derived EVs, they showed no 
modulation in proliferation and differentiation, being comparable 
to the control condition, but they showed an increased capability  
to migrate and to form colonies in soft agar, therefore acquiring 
typical features of tumour cells. For these reasons, we investigated 
the expression of osteoblastic and tumorigenic markers in EV-
treated hOBs. Among mRNAs studied, we highlighted the 
enhanced expression of RUNX2 and TNF-α in hOBs that received 
osteosarcoma-derived EVs. The correlation between high 
expression of RUNX2 and the oncogenesis of bone tumours as 
well as bone metastases has been already described
100
 thus 
strengthening our hypothesis of EV involvement in the vicious 
cycle established between osteosarcoma and bone cells. 
As regards osteoclasts and osteoclast precursors response to EV 
treatments, we found a great induction of proliferation following 
HOS-derived EV treatment of monocytes, as well as the formation 
of TRAP
+
 multinucleated cells after two weeks of treatment, 
Enrica Urciuoli 
Pag 58  
although in a lower amount than canonical treatment (M-CSF and 
RANKL). Since we obtained this finding by treating monocytes 
with only osteosarcoma-derived EVs and without pro-
osteoclastogenic cytokines, the presence of TRAP
+
 multinucleated 
osteoclasts, although in a low amount, represents a first evidence 
of EV capability to support, alone, osteoclastogenesis. Indeed, by 
FACS analysis we confirmed the presence of MCSF, RANK and 
RANKL in EVs derived from all 3 type of osteosarcoma cell lines, 
although in different quantities. Therefore, analysing these data, we 
can conclude that osteosarcoma EVs are able to alter the balance of 
bone homeostasis and to induce non-canonical differentiation and 
tumorigenic mechanisms in normal cells, that can be associated to 
osteosarcoma oncogenesis. 
Once demonstrated the crucial role of these nanoparticles in 
tumour cell communication, we tried to exploit this mechanism by 
using EVs as prognostic marker. GD2 ganglioside is a well known 
marker for detection of neuroblastoma
101,102
 and is expressed also 
in osteosarcoma patients
97
. Hence, we demonstrated that EVs 
derived from osteosarcoma cell lines with increasing 
aggressiveness showed increasing expression of GD2 marker. This 
finding can be useful in the prognostic and diagnostic approaches 
to osteosarcoma, in particular considering that EVs can be very 
easily detected and isolated from the bloodstream and other 
biological fluids.  
Finally, considering the transforming power of osteosarcoma EVs, 
we studied the possibility to inhibit the extracellular secretion of 
these vesicles.  
Starting from data in the literature showing the suppression of 
osteosarcoma by the inhibition of ROCK signalling and the role of 
GTPase RhoA to trigger a specific signalling pathway essential for 
microvesicles biogenesis
103,104
, we evaluated the effects of 
cytoskeleton remodeling on the EV production in osteosarcoma 
cell lines treated with the protein kinase ROCK inhibitor, Y-27632. 
This treatment reduced the amount of EVs produced by tumour 
cells, thereby strengthening the feasibility to use this drug in the 
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therapeutic approach to osteosarcoma patients and further 
underlining the involvement of EV signalling in oncogenesis.  
Our work highlights the relevance of EV shedding by 
osteosarcoma cells as a crucial process exploited by tumour to alter 
the microenvironment in which it arises. In this context, we 
demonstrated that tumoral EVs may be involved in cancer onset 
and progression, especially by transforming normal cells of the 
tumour microenvironment. This effect would be consistent with the 
idea that the expansion of a tumour mass would not necessarily 
depend solely on the proliferation of the cancer cells but rather 
could include as well the aberrant growth of normal cells exposed 
to tumour-derived EVs. Should this notion turns out to be true,   
the scientific community needs to adjust the common 
understanding of cancer progression in vivo, by including the 
potential contribution of EVs. 
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6. Materials & Methods 
 
6.1 Cell culture 
The human osteosarcoma cell lines and NIH3T3 were purchased 
from ATCC.  
Primary human femoral osteoblasts and primary human fibroblasts  
were purchased from ScienCell™. 
Isolation of mononuclear cells and ex vivo expansion of MSCs 
were performed from healthy donors who donate bone marrow 
cells for transplantation at the Bambino Gesù Children’s Hospital, 
as described in Bernardo et al. work
105
. Briefly, mononuclear cells 
were obtained from bone marrow aspirates of HDs by density 
gradient centrifugation (Ficoll 1.077 g/ml; Lympholyte, Cedarlane 
Laboratories Ltd.) and plated in noncoated 75-175 cm
2
 tissue 
culture flasks (BD Falcon) at a density of 160.000/cm
2
 in complete 
culture medium: DMEM (Eurocloney) supplemented with 10% 
fetal bovine serum (FBS, Gibco), 100 units/ml penicillin/ 
streptomycin (Euroclone) and 2mM L-glutamine (Euroclone). 
Cultures were maintained at 37°C in a humidified atmosphere, 
containing 5% CO2. After 48 hours in adhesion, non-adherent cells 
were removed and culture medium was replaced twice a week. 
MSCs were harvested, after reaching about 80% confluence, using 
Trypsin (Euroclone), and they were propagate at 4.000 cells/cm
2
 
All cell lines were grown in Dulbecco’s modified Eagle’s medium 
(DMEM) (Euroclone) supplemented with 10% FBS, 100 units/ml 
penicillin/streptomycin (Euroclone) and maintained at 37 °C in 5% 
CO2. 
The treatment of NIH3T3 in low serum condition was performed 
by using  DMEM supplemented with  2% FBS or 0,25% BSA. 
The osteogenic differentiation capacity of MSCs was assessed at 
passage 3, we platelet MSCs at density of 2x10
4
 in 24-well and for 
7 days we used DMEM supplemented with 10% FBS, 
Dexametasone (10μM) (Sigma-Aldrich) and L-Ascorbic acid 
(25mM) (Sigma-Aldrich). After a week, we added to media β-
Glycerophosphate disodium salt hydrate (5mM) (Sigma-Aldrich). 
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We treated MSCs for 21 days, then, to detect osteogenic 
differentiation, Alkaline Phosphatase, Leukocye Kit (Sigma-
Aldrich) was used to assess ALP activity, according to 
manufacturer’s instruction, while mineralization  was evaluated by 
staining  calcium deposition with Alizarin Red (Sigma-Aldrich).  
Human primary monocytes were isolated from healthy-donor bone 
marrow by centrifugation on Histopaque 1077 (Sigma-Aldrich) 
and cultured in 96-multiwell plates for 2 weeks to assess 
osteoclastogenesis. Monocytes were treated with 20 ng/ml 
macrophage colony stimulation factor (MCSF) (Tebubio) to induce 
proliferation, and with 20 ng/ml MCSF and 30 ng/ml RANKL 
(Tebubio) to induce osteoclasts formation. Acid Phosphatase, 
Leukocyte (TRAP) kit (Sigma-Aldrich) was used to assess TRAP 
activity, according to manufacturer’s instructions. 
For pharmacological treatment, Saos-2, HOS and 143B cell lines 
were treated with 20μM of Y-27632 (Sigma-Aldrich) for 24h.  
 
6.2 EV collection  
Osteosarcoma cell lines were platelet at density of 2x10
6
 in T75  
flasks. In the conditioned medium experiments, to remove 
endogenous EVs, FBS added to DMEM medium was 
ultracentrifuged at 100,000 g by Optima XPN-100 Ultracentrifuge 
(Beckman Coulter) before use. The media were collected after 24h 
of conditioning, centrifuged 1,500rpm for 10 min to eliminate cell 
debris and split in 3 equal amounts to test 3 different isolation 
protocols: (i) the medium was ultracentrifuged at 100,000g for 1h 
at 4°C to collect EVs on the bottom of tube; (ii) the medium was 
concentrated by centrifugation for 20 min at 2,000g in sterile 
hydrated 30 kDa MWCO Amicon Ultra Centrifugal filters 
(Millipore); (iii) the medium was incubated in a ratio of 1:10 with 
ExoQuick™, according to the manufacturer’s instructions. 
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6.3 Stainings and confocal microscopy analysis 
Osteosarcoma cell lines were stained with CFSE (1mM) (Life 
Technologies) and PKH-26 (Sigma-Aldrich) dyes, according to the 
manufacturer’s instruction. 
To visualize actin, cell lines were fixed with 4% paraformaldehyde 
and incubated with rhodamine-conjugated phalloidin, using 
Hoechst to stain nuclei. 
The confocal microscopy imaging was performed on a Leica TCS-
SP8X laser-scanning confocal microscope (Leica Mycrosystem, 
Mannheim,Germany) equipped with tunable white light laser 
(WLL) sourse, 405nm diode laser, 3 Internal Spectral Detector 
Channel (PMT) and 2 Internal Spectral Detector Channels (HyD) 
GaAsP. Sequential confocal images are acquired using a 
HCPLAPO 63x oil-immersion objective with a 1024x1024 format, 
scan speed 400Hz, and z-step size of 0.25 μm.  Z-reconstructions 
are imported into LASX 3D Analysis (Leica Microsystems) 
software to obtain the three-dimensional surface rendering. 
 
6.4 Flowcytometric analysis 
To visualize EVs, we used nanobeads (Spherotech) with known 
size of 0.5, 0.7 and 1.3 μm to create the gate in which visualize 
EVs. Moreover, we used 5.000 CountBright™ Absolute Counting 
Beads (Life Technologies) to evaluate the same volume (5μl) for 
each samples. EVs, NIH3T3 and osteosarcoma cell lines were 
analysed with FACSAria II flow cytometer (BD PharMigen) and 
data were calculated using the FACSDiva software (Tree 
Star,Inc.).  
Primary antibodies: anti human CD63-Alexa Fluor 488, anti 
human RANK-PE conjugated and anti human RANKL-PE 
conjugated were purchased by Thermo Fisher Scientific, anti 
human MCSF-PE conjugated was by R&D SYSTEMS
®
. 
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6.5 EV quantities analysis 
EXOCET 
To quantify isolated EVs, we used EXOCET (SBI,System 
Biosciences) according to the manufacturer’s instructions. This is a 
quantification assay kit designed as a direct measurement of 
esterase activity known to be within EVs. 
 
Tunable Resistive Pulse Sensing (TRPS) Technology. 
The isolated EVs were resuspended in 150μl of PBS. TRPS 
analysis were performed by Izon Science that provided information 
about amount of particles/ml for each analysed sample and their 
size range. 
 
6.6 Western Blotting  
NIH3T3 and EV pellet were collected and total protein extraction 
was performed by homogenizing cells in Ripa lysis buffer (Cell 
Signalling Technology) containing 1X protease and phosphatase 
inhibitors cocktail. The homogenates were then centrifuged at 
13,000 rpm at +4° for 10 minutes and the resulting supernatant was 
taken as protein sample. Cell and EV extracts were quantified 
using the BCA™ Protein Assay (Thermo Scientific). Samples were 
then diluted in the sample buffer (200 mM Tris-HCl (pH 6.8), 20% 
β-mercaptoethanol,4% sodium dodecyl sulphate, and bromophenol 
blue) and resolved in SDS-PAGE, then transferred and 
immobilized onto nitrocellulose membranes (Amersham). The 
membranes were blocked using 5% BSA for 30 min and incubated 
with the appropriate primary and secondary antibodies. Signal 
intensity was measured with a ChemiDoc Imaging System 
(BioRad). 
Primary antibodies: anti AKT, pAKT, ERK1/2, pERK1/2  were 
from Cell Signalling Technology; anti GAPDH were supplied by 
Sigma-Aldrich; anti CD63 were from Thermo Fisher Scientific. 
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6.7 Apoptosis analysis 
Cells were harvested by trypsinization, washed with PBS, then 
stained with a solution containing 1 mg/ml Propidium Iodide (PI). 
Apoptosis was analyzed with an APC Annexin V Apoptosis 
Detection Kit (BD Pharmingen, BD Biosciences) according to the 
manufacturer’s instructions. The fluorescent intensity was 
measured by BD FACSCanto Flow Cytometer (BD Biosciences). 
Resulting Annexin distributions were analysed for the proportions 
of cells defined as Live, Early apoptosis, Late apoptosis and Death. 
 
6.8 Cell cycle analysis  
Cell cycle phase distribution was analyzed by flow cytometry 
using Propidium Iodide (PI) staining. Briefly, NIH3T3 cells were 
harvested by trypsinization, washed with PBS, then fixed in a 
solution of a cold 4:1 methanol/acetone solution. Cells were then 
stained with a solution containing 100μg/ml PI and 0.1 mg/ml 
RNase A. Stained nuclei were analysed for DNA-PI fluorescence 
using a Becton Dickinson FACSCanto flow cytometer. Resulting 
DNA distributions were analysed for the proportions of cells in 
G0-G1, S and G2-M phases of the cell cycle. 
 
6.9 Wound healing assay 
NIH3T3 and human osteoblasts were platelet at density of 
3x10
5
/ml in Culture-Inserts (Ibidi), then removed after 24h. 
Following 5h of EV treatment, cells were fixed with 4% 
paraformaldehyde, stained with the nuclear dye Hoechst and the 
wound size was analysed using ImageJ software. 
 
6.10 Soft agar assay  
Anchorage-independent growth was determined by soft agar assay. 
A base layer of complete culture medium in 1% agar was 
established in 12-well. NIH3T3 cells were plated at 1x10
4
 cells per 
well in the top layer composed of the same culture medium and 
0,7% agar mixture. Growth medium and the treatment with 
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osteosarcoma-derived-EV was refreshed every 2-3 days. After 30 
days, colonies were counted under a light microscope (10X).  
 
6.11 RT–PCR 
Total RNA was extracted from cultured cells using the standard 
Trizol procedure. Each RNA sample was quantified by NanoDrop 
2000 (Thermo Scientific). Two μg of RNA were reverse 
transcribed using the SuperScript
™
 II Reverse Transcriptase 
(Invitrogen) to generate cDNA. These were carried out in a final 
volume of 20 μl containing 100 μM of each primer and 
REDTaq
®
Ready Mix (Sigma-Aldrich). Gapdh was used as 
housekeeping. PCR-amplified products were analysed on 2% 
agarose gel containing Gel Red (Biotium), signal intensity was 
measured with a ChemiDoc Imaging System and densitometry 
analysis performed by the Quantity One Software (BioRad). 
Primer pairs 5’-3’: 
mouse GAPDH reverse: TGAAGGGGTCGTTGATGGC 
mouse GAPDH forward: CCTCGTCCCGTAGACAAAATG 
mouse ALP reverse: TGACGTTCCGATCCTGAGTG 
mouse ALP forward: TGGTCACAGCAGTTGGTAGC 
mouse MMP-9 reverse: GCGGTACAAGTATGCCTCTGC 
mouse MMP-9 forward: CAAAGGCAGCGTTAGCCAGA 
human GAPDH reverse: GACAAGCTTCCCGTTCTCAG 
human GAPDH forward: ACAGTCAGCCGCATCTTCTT 
human ALP reverse: CCACCAAATGTGAAGACGTG 
human ALP forward: GGACATGCAGTACGAGCTGA 
human COLL1A2 reverse: GGCGTGATGGCTTATTTGTT 
human COLL1A2 forward: CTGCAAGAACAGCATTGCAT 
human RUNX2 reverse: TATGGAGTGCTGCTGGTCTG 
human RUNX2 forward: TTACTTACACCCCGCCAGTC 
human TNF-α reverse: AGGCCCCAGTTTGAATTCTT 
human TNF-α forward: TCCTTCAGACACCCTCAACC 
human TGF-β reverse: CCGGTAGTGAACCCGTTGAT 
human TGF-β forward: TACCTGAACCCGTGTTGCTC 
human IL6 reverse: CAGGGGTGGTTATTGCATCT 
human IL6 forward: AAAGAGGCACTGGCAGAAAA 
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